Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.52 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28168304 | 0.86 | ROCK2 (0.56) | ROCK2SCD5OPRM1OPRK1ADAM17 | |
| SCHEMBL8542566 | 0.81 | ROCK2 (0.62) | ROCK2SCD5HSD17B10KDM4EALDH1A1 | |
| SCHEMBL21392834 | 0.80 | HSD17B10 (0.54) | SCD5OPRM1OPRK1HSD17B10KDM4E | |
| SCHEMBL21392963 | 0.80 | ALDH1A1 (0.48) | HSD17B10KDM4EALDH1A1LMNA | |
| SCHEMBL18520901 | 0.80 | ROCK2 (0.45) | ROCK2SCD5OPRM1OPRK1ADAM17 | |
| SCHEMBL18510351 | 0.78 | FKBP1A (0.52) | ROCK2SCD5ADAM17 | |
| SCHEMBL27382202 | 0.78 | DRD2 (0.57) | ROCK2KDM4EALDH1A1LMNA | |
| SCHEMBL19151688 | 0.77 | ADAM17 (0.54) | ROCK2SCD5OPRM1OPRK1ADAM17 | |
| SCHEMBL31518180 | 0.76 | KDM4E (0.48) | SCD5OPRM1HSD17B10KDM4EALDH1A1 | |
| SCHEMBL28056141 | 0.76 | PPID (0.74) | ROCK2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666661-B2 | Methods and compounds for targeted autophagy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-06 | — | — | US | disclosed |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-02 | — | — | US | disclosed |
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | FRONTIER MEDICINES CORPORATION | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290778-A1 | METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY | ATG7, BECN1, SQSTM1 | ROCK2 872/4885SCD5 2052/4885OPRM1 4145/4885 |
| US-20210369731-A1 | COVALENT TARGETING OF E3 LIGASES | RNF114, RNF4, RNF168 | ROCK2 3151/4885SCD5 4266/4885OPRM1 4613/4885 |
| US-11666661-B2 | Methods and compounds for targeted autophagy | ATG7, BECN1, SQSTM1 | ROCK2 872/4885SCD5 2052/4885OPRM1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.